These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. Kõks S; Männistö PT; Bourin M; Shlik J; Vasar V; Vasar E J Psychiatry Neurosci; 2000 Jan; 25(1):33-42. PubMed ID: 10721682 [TBL] [Abstract][Full Text] [Related]
25. Role of cholecystokinin and opioid peptides in control of food intake. Baile CA; McLaughlin CL; Della-Fera MA Physiol Rev; 1986 Jan; 66(1):172-234. PubMed ID: 2868468 [TBL] [Abstract][Full Text] [Related]
26. The role of cholecystokinin in the induction of aggressive behavior: a focus on the available experimental data (review). Katsouni E; Zarros A; Skandali N; Tsakiris S; Lappas D Acta Physiol Hung; 2013 Dec; 100(4):361-77. PubMed ID: 24317345 [TBL] [Abstract][Full Text] [Related]
27. Cholecystokinin in the entero-insular axis. Okabayashi Y; Otsuki M; Baba S Diabetes Res Clin Pract; 1989; 7 Suppl 1():S79-85. PubMed ID: 2680370 [TBL] [Abstract][Full Text] [Related]
28. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin. Altar CA; Boyar WC Brain Res; 1989 Apr; 483(2):321-6. PubMed ID: 2706523 [TBL] [Abstract][Full Text] [Related]
29. Clinical endocrinology and metabolism. Cholecystokinin. Rehfeld JF Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):569-86. PubMed ID: 15533776 [TBL] [Abstract][Full Text] [Related]
33. The cholecystokinin hypothesis of anxiety and panic disorder. Bradwejn J; Koszycki D Ann N Y Acad Sci; 1994 Mar; 713():273-82. PubMed ID: 8185169 [No Abstract] [Full Text] [Related]
34. CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons. Rasmussen K Ann N Y Acad Sci; 1994 Mar; 713():300-11. PubMed ID: 8185172 [No Abstract] [Full Text] [Related]
35. Cholecystokinin-induced gastroprotection: a review of current protective mechanisms. West SD; Mercer DW Dig Dis Sci; 2004 Mar; 49(3):361-9. PubMed ID: 15139482 [TBL] [Abstract][Full Text] [Related]
36. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Hebb AL; Poulin JF; Roach SP; Zacharko RM; Drolet G Prog Neuropsychopharmacol Biol Psychiatry; 2005 Dec; 29(8):1225-38. PubMed ID: 16242828 [TBL] [Abstract][Full Text] [Related]
37. Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models. Rotzinger S; Vaccarino FJ J Psychiatry Neurosci; 2003 May; 28(3):171-81. PubMed ID: 12790157 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic and chemical developments of cholecystokinin receptor ligands. de Tullio P; Delarge J; Pirotte B Expert Opin Investig Drugs; 2000 Jan; 9(1):129-46. PubMed ID: 11060666 [TBL] [Abstract][Full Text] [Related]
39. Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists. Hughes J; Hunter JC; Woodruff GN Neuropeptides; 1991 Jul; 19 Suppl():85-9. PubMed ID: 1679213 [No Abstract] [Full Text] [Related]
40. Release of cholecystokinin in the central nervous system. Raiteri M; Paudice P; Vallebuona F Neurochem Int; 1993 Jun; 22(6):519-27. PubMed ID: 8513278 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]